載入中
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
前收盤價
US$2.46
+US$0.12 · +5.13%
盤中時間採用ET。市場資料可能有所延遲。
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
日內區間
目前US$2.46
52週區間
目前US$2.46
盤中時間採用ET。市場資料可能有所延遲。
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
日內區間
目前US$2.46
52週區間
目前US$2.46
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 725.2萬 USD | 56.6萬 USD | 39.2萬 USD | 150.27萬 USD | 2.08億 USD |
| 銷貨成本 | 30萬 USD | — | — | — | — |
| 毛利 | 695.2萬 USD | 56.6萬 USD | 39.2萬 USD | 150.27萬 USD | 2.08億 USD |
| 研究與開發 | 2558.2萬 USD | 3676.7萬 USD | 2858.8萬 USD | 2461.84萬 USD | 4693.96萬 USD |
| 銷售、一般及管理費用 | 2410.9萬 USD | 2568.3萬 USD | 2958.5萬 USD | 3243.2萬 USD | 3723.3萬 USD |
| 營業費用 | 4939.1萬 USD | 6245.1萬 USD | 5967.3萬 USD | 5705.09萬 USD | 8417.37萬 USD |
| 利息收入 | — | 390萬 USD | 490萬 USD | — | — |
| 折舊和攤銷 | 27.3萬 USD | 61.3萬 USD | 56.8萬 USD | 138.16萬 USD | 23.71萬 USD |
| 營業利益 | −4243.9萬 USD | −6188.5萬 USD | −5928.1萬 USD | −5554.82萬 USD | 1.24億 USD |
| 淨利 | −1741.4萬 USD | −2643.3萬 USD | −5233.9萬 USD | −5416.9萬 USD | 1.23億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.67
上漲空間 171.14%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1509.41萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1005.76萬0.01%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI658.26萬0.07%98.74億 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF527.54萬0.01%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO234.68萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC122.19萬0.09%13.17億 USD0.60%US$183+0.11%
Fidelity Enhanced Small Cap ETFFESM121.02萬0.02%64.1億 USD0.28%US$45.46+0.46%
iShares Core S&P Total U.S. Stock Market ETFITOT80.35萬0.00%980.88億 USD0.03%US$169.66+0.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMiShares Core S&P Total U.S. Stock Market ETFITOTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
